Fig. 5

Therapeutic PLX3397 treatment (days 30–70 post-transplant) reduces neuroinflammation in the cGVHD brain. A Experimental timeline for control chow and/or PLX3397 (300 ppm) treatment, given between days 30 and 70 post-transplant, for syngeneic and cGVHD mice. B Quantification of IBA1^pos cell density in the hippocampus of syngeneic controls and cGVHD mice with and without PLX3397 treatment (days 70–100 post-transplant). Asterisks indicate post-hoc results. C Representative confocal images of IBA1^pos (green) and MHCII^pos (red) cells in the hippocampus of syngeneic controls and cGVHD mice with and without PLX3397 treatment Scale bar = 100 µm. D Quantification of MHCII^pos cell density in the hippocampus of syngeneic controls and cGVHD mice with and without PLX3397 treatment (days 70–100 post-transplant). Asterisks indicate post-hoc results. E Quantification of GFAP^pos cell density in the hippocampusof syngeneic controls and cGVHD mice with and without PLX3397 treatment (days 70–100 post-transplant). F Representative confocal images of GFAP^pos cells (green) in the hippocampus of syngeneic controls and cGVHD mice with either control chow or PLX3397 (300 ppm) treatment. Cell nuclei are labelled with DAPI (blue). Scale bar = 100 µm. G Quantification of the GFAP immunoreactive area in the hippocampus of syngeneic controls and cGVHD mice with and without PLX3397 treatment (H) Quantification of the mean fluorescence intensity (MFI) for GFAP staining in the hippocampus of syngeneic controls and cGVHD mice with and without PLX3397 treatment. Statistics: one-way ANOVA (B, D, E, G, H) followed by Bonferroni post hoc comparison. C, F Scale bar: 100 µm. Dots in box plots represent individual mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001